Evaluation of 2-(4-Chlorophenyl)-4-(4-fluorophenyl)-5-pyridin-4-yl-1,2-dihydropyrazol-3-one as a p38 MAPK inhibitor in MCF-7 and MDA-MB-231 breast cancer cell lines. Al Mustansiriyah Journal of Pharmaceutical Sciences, [S. l.], v. 25, n. 3, p. 317–326, 2025. DOI: 10.32947/ajps.v25i3.1224. Disponível em: https://ajps.uomustansiriyah.edu.iq/index.php/AJPS/article/view/1224. Acesso em: 28 jun. 2026.